GlassScriptPhysician profile
Kristen Belanger
NPI 1366443376
$1,216.90
in general payments reported to CMS, 2019-2025
11 companies · $520 in 2025
The $520 reported for 2025 was more than what 93% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.82 · 2021: $13.11 · 2022: $119 · 2023: $257 · 2024: $268 · 2025: $520.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,045.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $338.24 | 2023-2025 | Caplyta |
| Indivior INC. | $285.30 | 2019-2025 | Sublocade |
| Abbvie INC. | $118.93 | 2022-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $104.44 | 2021-2025 | Abilify Asimtufii, Rexulti, Abilify Maintena |
| Braeburn INC. | $87.94 | 2023-2025 | Brixadi |
| Alkermes, INC. | $87.26 | 2019-2023 | Vivitrol |
| Axsome Therapeutics, INC. | $56.33 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $48.70 | 2023-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $34.45 | 2025 | Austedo Xr, Uzedy |
| Janssen Pharmaceuticals, INC | $27.71 | 2023 | Invega Trinza, Invega Sustenna |
| Luye Pharma (USA) LTD. | $27.60 | 2025 | Erzofri Extended-Release |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Belanger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.